A hospital in Chongqing's downtown area was sealed for serious fires

A hospital in Chongqing's main city was shut down due to a serious fire disaster, diesel generator | diesel generator price / 2012-05-05

Chongqing, May 5th On the 4th, Chongqing Jiuzhou Hospital, located in the main urban area of ​​Chongqing, was seized by the fire department because of serious fire problems.
According to the law enforcement officers of the public security and fire supervision in Banan District, Chongqing Municipality, there is no automatic sprinkler system installed in Chongqing Jiuzhou Hospital, no closed stairwell has been formed, the automatic fire alarm system has been damaged, some evacuation indicator signs have been damaged, and the number of smoke detectors is insufficient. Fire hazards such as safety exit locks pose a serious threat to public safety.
On the same day, the fire supervision and law enforcement personnel banned the Chongqing Jiuzhou Hospital in accordance with the law, and reported the related firefighting hazards to the person in charge of the hospital. They issued a “correction order” to the hospital and ordered them to complete the correction within one month.
Considering that there are still patients in the hospital undergoing treatment, law enforcement officials require that some departments of the hospital perform various firefighting tasks during the “disease management” period to ensure safety during rectification.
Next:Installation, use and regulation of marine diesel generator sets
Previous post:Women's disease rips 50,000 yuan into pieces. Husband resigns to fight at home.

Ponatinib API

Ponatinib is an orally bioavailable multitargeted receptor tyrosine kinase (RTK) inhibitor with potential antiangiogenic and antineoplastic activities. Ponatinib inhibits unmutated and all mutated forms of Bcr-Abl, including T315I, the highly drug therapy-resistant missense mutation of Bcr-Abl. This agent also inhibits other tyrosine kinases including those associated with vascular endothelial growth factor receptors (VEGFRs) and fibroblast growth factor receptors (FGFRs); in addition, it inhibits the tyrosine kinase receptor TIE2 and FMS-related tyrosine kinase receptor-3 (Flt3). RTK inhibition by ponatinib may result in the inhibition of cellular proliferation and angiogenesis and may induce cell death. Bcr-Abl is a fusion tyrosine kinase encoded by the Philadelphia chromosome.

Ponatinib is a tyrosine kinase receptor inhibitor that is used in the therapy of refractory chronic myelogenous leukemia (CML) positive for the Philadelphia chromosome. Ponatinib is commonly associated with transient elevations in serum aminotransferase levels during treatment, but with only rare instances of clinically apparent acute liver injury.

Ponatinib Api,Ponatinib Cas 943319-70-8,Ap24534 Ponatinib Cs-165,Iclusig Ponatinib Api

 Shandong Haohong Biotechnology Co., Ltd. , https://www.haohongpharma.com

Posted on